Israeli Biotech Polyrizon Completes Offering
Categories: Capital Markets
Polyrizon Ltd., an Israeli biotechnology company focused on developing protective nasal therapies to prevent respiratory infections and environmental exposure, has completed a registered direct offering of ordinary shares.
The offering strengthens Polyrizon’s capital base as it continues product development and clinical advancement within the life sciences and biotech sector.
Greenberg Traurig (Tel Aviv) advised Polyrizon Ltd. on the transaction. The advising lawyers were David Huberman and Michael Soumas.
